SCHEMBL18477024

SCHEMBL18477024

COC(=O)c1ccc2c(c1)nc(OC1CCC(C(F)(F)F)CC1)n2C1CC1

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 7/20 0.64
▸ RPS6KB1 P23443 1/20 0.52
▸ IDH1 O75874 11/20 0.44
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18477022 0.91 RORC (0.60) RORCRPS6KB1IDH1
SCHEMBL18477020 0.89 RORC (0.62) RORCIDH1
SCHEMBL20465151 0.88 RORC (0.58) RORCRPS6KB1IDH1
SCHEMBL20465152 0.87 RPS6KB1 (0.55) RORCRPS6KB1IDH1KDM4E
SCHEMBL20465159 0.76 L3MBTL1 (0.56) RORCRPS6KB1IDH1
SCHEMBL20454463 0.76 RORC (0.77) RORC
SCHEMBL18477019 0.76 RPS6KB1 (0.55) RPS6KB1IDH1KDM4E
SCHEMBL15551563 0.74 EPHX2 (0.48) KDM4E
SCHEMBL15551565 0.74 EPHX2 (0.48) KDM4E
SCHEMBL21311021 0.72 RPS6KB1 (0.57) RPS6KB1IDH1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210300869-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICAL, LLC 2021-09-30 — — US disclosed
US-10829448-B2 Substituted benzoimidazoles as modulators of ROR-γ VITAE PHARMACEUTICALS, LLC (US) 2020-11-10 — — US disclosed
EP-3331876-B1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS LLC (US) 2020-10-07 — — EP disclosed
US-20200062707-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, INC. 2020-02-27 — — US disclosed
US-10301261-B2 Substituted indoles as modulators of ROR-gamma VITAE PHARMACEUTICALS, LLC (US) 2019-05-28 — — US disclosed
US-20180222860-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, LLC 2018-08-09 — — US disclosed
WO-2017024018-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, INC. (US) 2017-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301261-B2 Substituted indoles as modulators of ROR-gamma RORB, RORC, RORA RORC 2/4885RPS6KB1 363/4885IDH1 2823/4885
US-20200062707-A1 MODULATORS OF ROR-GAMMA RORB, RORC, RORA RORC 2/4885RPS6KB1 191/4885IDH1 3584/4885
US-20180222860-A1 MODULATORS OF ROR-GAMMA RORB, RORC, RORA RORC 2/4885RPS6KB1 191/4885IDH1 3584/4885
US-10829448-B2 Substituted benzoimidazoles as modulators of ROR-γ RORC, RORB, RORA RORC 1/4885RPS6KB1 401/4885IDH1 988/4885
US-20210300869-A1 MODULATORS OF ROR-GAMMA RORC, RORB, RORA RORC 1/4885RPS6KB1 503/4885IDH1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback